Navigation Links
OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference
Date:2/6/2013

able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward look
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec Medical to Present at Noble Financial Capital Markets Ninth Annual Equity Conference on January 22
2. OncoSec Medical Announces $7.2 Million Public Offering
3. OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
4. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
5. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
6. OncoSec to Present at Upcoming Healthcare and Investor Conferences
7. OncoSec Granted New Patent from China
8. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
9. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
10. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
11. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Over 200 runners participated in ... Benefit the Radiation Oncology Institute (ROI), hosted by Radiation ... Gate Park in San Francisco.  "Donations ... CEO of Radiation Business Solutions, "but at this ... over $70,000 for the ROI this year. This surpasses ...
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/19/2014)... , September 19, 2014 Reductions ... for many years in people with diabetes type 2 ... long term benefits for the kidneys." Australian ... with type 2 diabetes leads to persistent reductions in ... The global study has found that, five ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Systems, Inc. (NASDAQ: DCTH ) announced today that ... agreement for the Delcath Hepatic CHEMOSAT ® Delivery system ... Oncologia ---IEO), a premier European cancer treatment and research center ... the Company will provide the IEO with logistics and clinical ...
... Reportlinker.com announces that a new ... its catalogue: , Frost & ... http://www.reportlinker.com/p0490686/Frost--Sullivan-Speaks-Candidly-with-US-Pharmacists.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmacies_and_Drug_Stores ... feedback provided by a healthcare pharmacist ...
Cached Medicine Technology:Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 2Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 3Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 4Frost & Sullivan Speaks Candidly with U.S. Pharmacists 2Frost & Sullivan Speaks Candidly with U.S. Pharmacists 3
(Date:9/19/2014)... Dallas, TX (PRWEB) September 19, 2014 ... which introduces a traditional Scandinavian style of ... United States. Much like Diet Doc’s medical ... Diet emphasizes cooking and eating good food ... diet also focuses on teaching patients to ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... by technological advancements, surgical techniques, and immunosuppressant drugs ... preferred treatment for several chronic diseases related to ... in organ and tissue transplantation have phenomenally revolutionized ... Organ transplant today represents a pivotal medical ...
(Date:9/19/2014)... as Johne,s disease, is caused by the bacterium ... Austria, there is a legal obligation to report ... treatment-resistant diarrhoea and wasting among affected animals. The ... farms. The animals produce less milk, exhibit fertility ... such as udder inflammation. , To date ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 InventHelp, ... clients, an inventor from New York, has created an accessory ... from inclement weather or smoke during transport. This invention ... to a stretcher and remain in place until removed, guarding ... a more comfortable move with protection from irritating smoke or ...
(Date:9/19/2014)... as released a new blog post announcing ... for life insurance. , Clients who have heart disorders ... not require medical examinations. No medical exam life insurance ... minutes. , Some traditional policies (that require medical ... health problems, however the application time is longer and ...
Breaking Medicine News(10 mins):Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:InventHelp® Client Patents “Patient Protector” – Designed to Protect Patients During Transport 2Health News:No Medical Exam Life Insurance For Clients Who Have Heart Problems! 2
... should reduce the salt intake to avoid high blood pressure and ... g per day//. FSA also stressed that the tinned foods should ... ,Too much of salt is very harmful to humans ... can lead to heart attacks. The amount of salt content is ...
... following ace cricketer Sachin Tendulkar's and several other players complaining ... the sports arena//. ,Tennis elbow, or lateral epicondylitis ... where the outer part of the elbow becomes painful and ... or a direct bang. The problem occurs following overuse of ...
... at high risk of fatal and non-fatal myocardial ... reason for their decreased life expectancy//. There is ... (PPAR-?) could reduce macrovascular complications. Pioglitazone is one ... ,A recent study, published in the October issue ...
... for cardiovascular disease in both men and women, which ... subjects and that 80 percent of all type 2 ... In these patients hyperglycemia per se confers ... of even borderline-high-risk LDL-C signals the need for more ...
... Odors have long been known to be capable of ... effects of essential oils have been acknowledged in folk ... lavender fragrances have been particularly attributed with mood enhancing ... the September issue of the journal Physiology & Behavior, ...
... the benefits of oral ZYVOX for the treatment of ... compared data from 80 health care clinics and compared ... The results show that oral tablets of Linezolid (ZYVOX), ... to health clinics compared to vancomycin. ,This ...
Cached Medicine News:Health News:Tennis elbow not new among cricketers, say experts 2Health News:Aromatherapy: Ambient odors of orange and lavender reduce anxiety 2Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2
Precision that fits in the palm of your hand and measures down to 125 microns, the Pocket Pachymeter is about 8" X 4" x 2" and really does fit in a lab coat pocket or briefcase....
15 segment Vertical Prism Bar provides 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30 PD (Note: 30 PD is on the bar). 4447 xx Vertical Prism Bar....
Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Sabre 180, 230V, 50Hz is a powerful niche generator....
Medicine Products: